▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #178 by analyst upside · 2026-09-29
TVRD
Tvardi Therapeutics, Inc.
Healthcare · Market Cap $18M · P/E 0x
ANALYST PRICE TARGET
+595.5%
implied upside to consensus target
Current Price $1.33
Consensus Target $9.25
Bull Target $14.0
Bear Target $3.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
1
52-Week Low $0.93
52-Week High $43.65
YTD Return -67.4%
FUNDAMENTALS
Market Cap $18M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.01
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.93
52-Week High $43.65
Current Price $1.33
Bear Target $3.0
Bull Target $14.0
● Now $1.33 ● Target $9.25
TRADING DATA
Avg Volume 2.3M
YTD Return -67.4%
Analyst Count 8
Consensus Buy
Upside to Target +595.5%
Last Updated 2026-09-29

ANALYST SUMMARY

Tvardi Therapeutics, Inc. (TVRD) is currently trading at $1.33 with a Wall Street consensus price target of $9.25, implying potential upside of 595.5% over the next 12 months. 8 analysts currently cover TVRD, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $3.0.

TVRD operates in the Healthcare sector with a market capitalisation of $18M. The stock is down 67.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.93 – $43.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TVRD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG - Reiterated
Buy → Buy 2026-07-30 38% win rate (8 calls)
Raymond James ↑ Upgrade
Market Perform → Outperform 2026-07-08 Building track record
BTIG reit
Buy → Buy 2026-07-07 38% win rate (8 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-06-08 31% win rate (48 calls)
Barclays ↓ Downgrade
Equal-Weight → Underweight 2026-04-20 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-04-01 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-04-01 14% win rate (7 calls)
BTIG reit
Buy → Buy 2026-04-01 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
31
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →